Pharmaceuticals division

Focused on organic production through fermentation, it has earned world-wide recognition

A production primarily destined for export

The pharmaceuticals division is dedicated to the manufacture of generic active pharmaceutical ingredients (APIs), mainly antibiotics and, to a lesser extent, anti-hypertensives and anti-ulcer drugs.

It focuses on biological manufacturing (strain research and maintenance, microbiological control, fermentation and industrial extraction), but also produces and obtains sterile products by chemical synthesis. Another important activity of the division is the production of APIs and custom-designed intermediates for third parties.

The main value of the pharmaceuticals division is its global leadership, through the mastery of fermentation processes, and its ability to produce sterile products. The complexity of these processes strongly limits the number of producers in the world.

Our customers are commercial laboratories and distributors, including the world's largest, who use our products as raw materials or intermediates for the manufacture of commercial pharmaceutical specialities.

The pharmaceuticals division exports more than 90% of its sales to some 50 countries on all continents. The main markets are Italy, India, Turkey, France, Japan and Switzerland.

Overview of the industrial fermenters
Overview of the industrial fermenters
Exterior of the synthesis plant at the Aranjuez factory.
Exterior of the multi-purpose synthesis plant
Exterior of the sterile products plant at the Aranjuez factory.
Exterior of the sterile products plant
Logo of the 3D Investment Plan
3D Plan presentation

Innovation in products and processes

The R&D centre of the pharmaceuticals division is located in the Aranjuez factory. It is mainly dedicated to the research and development of new products and to improving quality, environmental and safety processes.

This research work led to the discovery of fosfomycin and its antibiotic application in 1969.

This division has carried out a major modernisation and expansion of the capacity of its facilities, which has boosted the production of fermentation, synthesis and sterile plants, as well as the storage capacity of finished products.

As part of the 3D Plan launched by Ercros, the division is adapting production processes to the objectives of diversification, decarbonisation and digitalisation. In order to diversify its commercial portfolio, it is developing the incorporation of two new products: vancomycin and gentamicin, both belonging to the family of antibiotics produced by fermentation.



Actions undertaken and underway

Planta de productos estériles de Aranjuez

Thanks to the new facilities, sterilisation capacity has been expanded.

 3D Plan investments

Construction of the biological extraction plant

Almacén de producto terminado de la fábrica de Aranjuez

Warehouse for finished products

Financial year 2023

The pharmauticals division in figures


Share of Ercros sales

430 t

Annual production capacity




Target countries

Where do we sell our products?

<iframe title="Markets " aria-label="Donut Chart" id="datawrapper-chart-3TTJs" src="" scrolling="no" frameborder="0" style="width: 0; min-width: 100% !important; border: none;" height="652" data-external="1"></iframe><script type="text/javascript">!function(){"use strict";window.addEventListener("message",(function(a){if(void 0!["datawrapper-height"]){var e=document.querySelectorAll("iframe");for(var t in["datawrapper-height"])for(var r=0;r<e.length;r++)if(e[r].contentWindow===a.source){var["datawrapper-height"][t]+"px";e[r].style.height=i}}}))}();
Share of sales in 2023.

Voluntary agreements

Ercros subscribes agreements and programmes entailing the application of good practices and commitments that go beyond the legal limits, which specifically concern this division.

Related associations

The pharmaceuticals division builds alliances with the sectoral organisations related to its activity.



Spanish manufacturers of fine chemicals